{"id":1011555,"date":"2026-10-19T16:25:53","date_gmt":"2026-10-19T20:25:53","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/structure-therapeutics-announces-multiple-upcoming-presentations-at-obesityweek-2026\/"},"modified":"2026-10-19T16:25:53","modified_gmt":"2026-10-19T20:25:53","slug":"structure-therapeutics-announces-multiple-upcoming-presentations-at-obesityweek-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/structure-therapeutics-announces-multiple-upcoming-presentations-at-obesityweek-2026\/","title":{"rendered":"Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek\u00ae 2026"},"content":{"rendered":"
\n

SAN FRANCISCO, Oct. 19, 2026 (GLOBE NEWSWIRE) — Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on chronic weight management, today announced multiple upcoming poster presentations at The Obesity Society’s Annual Meeting, ObesityWeek\u00ae, taking place from November 14\u201317, 2026 in National Harbor, MD.<\/p>\n

\n Title:<\/strong> Aleniglipron in Participants Living with Overweight or Obesity: ACCESS Trial Open-Label Extension
Date\/Time:<\/strong> November 15, 2026, 2:30 p.m. \u2013 3:30 p.m. ET
Location:<\/strong> Exhibit Hall BCD<\/p>\n

\n Title:<\/strong> Dose-Ranging Effects of Aleniglipron, an Oral Small-Molecule GLP-1RA for Obesity: The ACCESS Trials
Date\/Time:<\/strong> November 15, 2026, 2:30 p.m. \u2013 3:30 p.m. ET
Location:<\/strong> Exhibit Hall BCD<\/p>\n

\n About Aleniglipron <\/strong>
\n
Aleniglipron (GSBR-1290) is an investigational, once-daily, orally available small molecule agonist of the glucagon-like peptide-1 (GLP-1) receptor, a clinically validated target for the treatment of obesity and type 2 diabetes mellitus. Discovered through Structure Therapeutics\u2019 structure-based drug discovery platform, aleniglipron was designed as a biased G protein-coupled receptor agonist that selectively activates the G-protein signaling pathway.<\/p>\n

\n About Structure Therapeutics<\/strong>
\n
Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, the Company has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage oral small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more people living with obesity around the world. For additional information, please visit\u00a0www.structuretx.com<\/a>.<\/p>\n

\n Investors:<\/strong>
\n
Corey Davis, Ph.D.
LifeSci Advisors, LLC
212-915-2577
cdavis@lifesciadvisors.com<\/a><\/p>\n

Jen Robinson
Structure Therapeutics Inc.
Jennifer.Robinson@structuretx.com<\/a><\/p>\n

\n Media:<\/strong>
\n
Dan Budwick
1AB
Dan@1abmedia.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

SAN FRANCISCO, Oct. 19, 2026 (GLOBE NEWSWIRE) — Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on chronic weight management, today announced multiple upcoming poster presentations at The Obesity Society’s Annual Meeting, ObesityWeek\u00ae, taking place from November 14\u201317, 2026 in National Harbor, MD. Title: Aleniglipron in Participants Living with Overweight or Obesity: ACCESS Trial Open-Label ExtensionDate\/Time: November 15, 2026, 2:30 p.m. \u2013 3:30 p.m. ETLocation: Exhibit Hall BCD Title: Dose-Ranging Effects of Aleniglipron, an Oral Small-Molecule GLP-1RA for Obesity: The ACCESS Trials Date\/Time: November 15, 2026, 2:30 p.m. \u2013 3:30 p.m. ETLocation: Exhibit Hall BCD About Aleniglipron Aleniglipron (GSBR-1290) is an investigational, once-daily, orally available small … <\/p>\n

Continue reading “Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek\u00ae 2026”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1011555","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nStructure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek\u00ae 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/structure-therapeutics-announces-multiple-upcoming-presentations-at-obesityweek-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek\u00ae 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN FRANCISCO, Oct. 19, 2026 (GLOBE NEWSWIRE) — Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on chronic weight management, today announced multiple upcoming poster presentations at The Obesity Society’s Annual Meeting, ObesityWeek\u00ae, taking place from November 14\u201317, 2026 in National Harbor, MD. Title: Aleniglipron in Participants Living with Overweight or Obesity: ACCESS Trial Open-Label ExtensionDate\/Time: November 15, 2026, 2:30 p.m. \u2013 3:30 p.m. ETLocation: Exhibit Hall BCD Title: Dose-Ranging Effects of Aleniglipron, an Oral Small-Molecule GLP-1RA for Obesity: The ACCESS Trials Date\/Time: November 15, 2026, 2:30 p.m. \u2013 3:30 p.m. ETLocation: Exhibit Hall BCD About Aleniglipron Aleniglipron (GSBR-1290) is an investigational, once-daily, orally available small … Continue reading "Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek\u00ae 2026"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/structure-therapeutics-announces-multiple-upcoming-presentations-at-obesityweek-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-19T20:25:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0ODc4MiM3OTA0MjY0IzIyNDYwMzg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/structure-therapeutics-announces-multiple-upcoming-presentations-at-obesityweek-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/structure-therapeutics-announces-multiple-upcoming-presentations-at-obesityweek-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek\u00ae 2026\",\"datePublished\":\"2026-10-19T20:25:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/structure-therapeutics-announces-multiple-upcoming-presentations-at-obesityweek-2026\\\/\"},\"wordCount\":286,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/structure-therapeutics-announces-multiple-upcoming-presentations-at-obesityweek-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0ODc4MiM3OTA0MjY0IzIyNDYwMzg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/structure-therapeutics-announces-multiple-upcoming-presentations-at-obesityweek-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/structure-therapeutics-announces-multiple-upcoming-presentations-at-obesityweek-2026\\\/\",\"name\":\"Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek\u00ae 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/structure-therapeutics-announces-multiple-upcoming-presentations-at-obesityweek-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/structure-therapeutics-announces-multiple-upcoming-presentations-at-obesityweek-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0ODc4MiM3OTA0MjY0IzIyNDYwMzg=\",\"datePublished\":\"2026-10-19T20:25:53+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/structure-therapeutics-announces-multiple-upcoming-presentations-at-obesityweek-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/structure-therapeutics-announces-multiple-upcoming-presentations-at-obesityweek-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/structure-therapeutics-announces-multiple-upcoming-presentations-at-obesityweek-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0ODc4MiM3OTA0MjY0IzIyNDYwMzg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0ODc4MiM3OTA0MjY0IzIyNDYwMzg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/structure-therapeutics-announces-multiple-upcoming-presentations-at-obesityweek-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek\u00ae 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek\u00ae 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/structure-therapeutics-announces-multiple-upcoming-presentations-at-obesityweek-2026\/","og_locale":"en_US","og_type":"article","og_title":"Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek\u00ae 2026 - Market Newsdesk","og_description":"SAN FRANCISCO, Oct. 19, 2026 (GLOBE NEWSWIRE) — Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on chronic weight management, today announced multiple upcoming poster presentations at The Obesity Society’s Annual Meeting, ObesityWeek\u00ae, taking place from November 14\u201317, 2026 in National Harbor, MD. Title: Aleniglipron in Participants Living with Overweight or Obesity: ACCESS Trial Open-Label ExtensionDate\/Time: November 15, 2026, 2:30 p.m. \u2013 3:30 p.m. ETLocation: Exhibit Hall BCD Title: Dose-Ranging Effects of Aleniglipron, an Oral Small-Molecule GLP-1RA for Obesity: The ACCESS Trials Date\/Time: November 15, 2026, 2:30 p.m. \u2013 3:30 p.m. ETLocation: Exhibit Hall BCD About Aleniglipron Aleniglipron (GSBR-1290) is an investigational, once-daily, orally available small … Continue reading \"Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek\u00ae 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/structure-therapeutics-announces-multiple-upcoming-presentations-at-obesityweek-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-19T20:25:53+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0ODc4MiM3OTA0MjY0IzIyNDYwMzg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/structure-therapeutics-announces-multiple-upcoming-presentations-at-obesityweek-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/structure-therapeutics-announces-multiple-upcoming-presentations-at-obesityweek-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek\u00ae 2026","datePublished":"2026-10-19T20:25:53+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/structure-therapeutics-announces-multiple-upcoming-presentations-at-obesityweek-2026\/"},"wordCount":286,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/structure-therapeutics-announces-multiple-upcoming-presentations-at-obesityweek-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0ODc4MiM3OTA0MjY0IzIyNDYwMzg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/structure-therapeutics-announces-multiple-upcoming-presentations-at-obesityweek-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/structure-therapeutics-announces-multiple-upcoming-presentations-at-obesityweek-2026\/","name":"Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek\u00ae 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/structure-therapeutics-announces-multiple-upcoming-presentations-at-obesityweek-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/structure-therapeutics-announces-multiple-upcoming-presentations-at-obesityweek-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0ODc4MiM3OTA0MjY0IzIyNDYwMzg=","datePublished":"2026-10-19T20:25:53+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/structure-therapeutics-announces-multiple-upcoming-presentations-at-obesityweek-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/structure-therapeutics-announces-multiple-upcoming-presentations-at-obesityweek-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/structure-therapeutics-announces-multiple-upcoming-presentations-at-obesityweek-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0ODc4MiM3OTA0MjY0IzIyNDYwMzg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0ODc4MiM3OTA0MjY0IzIyNDYwMzg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/structure-therapeutics-announces-multiple-upcoming-presentations-at-obesityweek-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek\u00ae 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1011555","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1011555"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1011555\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1011555"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1011555"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1011555"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}